Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Langenbeck's Archives of Surgery
Published in: Langenbeck's Archives of Surgery 6/2017

01-09-2017 | REVIEW ARTICLE

Bridging to liver transplantation in HCC patients

Authors: Dagmar Kollmann, Nazia Selzner, Markus Selzner

Published in: Langenbeck's Archives of Surgery | Issue 6/2017

Login to get access

Abstract

Background

Liver transplantation (LT) is the only cure for patients diagnosed with unresectable hepatocellular carcinoma (HCC), and HCC has become the leading indication for LT in the USA. The shortage of liver grafts results in a significant waiting time for LT with the risk of tumour progression. Treating HCCs during the waiting time prior to transplantation (bridging therapy) is an attractive strategy to reduce the risk of exceeding the tumour criteria for transplantation. Studies on bridging therapy are heterogenous and due to ethical issues, mostly of retrospective design.

Purpose

We summarize the main studies and methods that have been reported on bridging therapies for patients with HCC waiting for a LT.

Conclusion

During the waiting period for LT, patients with HCC at risk for tumour progression and therefore bridging therapy is recommended for patients with an estimated waiting time of ≥6 months. Bridging therapy for patients with HCC prior to LT mainly include locoregional therapies (LRTs), with transarterial chemoembolization (TACE) being the most common, followed by radio frequency ablation (RFA). Because of a continuous enhancement of therapy options, including a more precise adjustment of external radiotherapy, further possibilities for an individualized bridging therapy for patients with HCC have been developed. Patients with compensated liver cirrhosis and small tumour size are preferably treated with RFA, whereas patients with larger tumour size but compensated liver function are treated with TACE/TARE. Patients with uncompensated liver cirrhosis and larger tumour size can nowadays be successfully bridged to LT with external radiotherapy without increasing the risk for further deterioration of liver function.
Literature
1.
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781PubMedCrossRef
2.
Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M et al (2017) Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 67(2):302–309
3.
Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ et al (2017) Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin Gastroenterol Hepatol 15(5):767–775 e3PubMedCrossRef
4.
5.
6.
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58(3):593–608PubMedCrossRef
7.
Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP (2007) Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7(11):2587–2596PubMedCrossRef
8.
Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A et al (2016) The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology 64(6):2077–2088PubMedCrossRef
9.
Hoffmann K, Hinz U, Hillebrand N, Radeleff BA, Ganten TM, Schirmacher P et al (2011) Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clin Transpl 25(5):E541–E551CrossRef
10.
Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N et al (2014) Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation 97(2):220–226PubMedCrossRef
11.
Bruix J, Sherman M (2011) American Association for the Study of liver D. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedPubMedCentralCrossRef
12.
13.
Bhardwaj N, Perera MT, Silva MA (2016) Current treatment approaches to HCC with a special consideration to transplantation. J Transp Secur 2016:7926264
14.
European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef
15.
Young AL, Adair R, Prasad KR, Toogood GJ, Lodge JP (2012) Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes. J Am Coll Surg 214(2):174–183PubMedCrossRef
16.
Yeh CN, Lee WC, Chen MF (2003) Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang gung memorial hospital. Ann Surg Oncol 10(9):1070–1076PubMedCrossRef
17.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699PubMedCrossRef
18.
Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6):1434–1440PubMedCrossRef
19.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 35(3):421–430PubMedCrossRef
20.
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A et al (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13(1):e11–e22PubMedCrossRef
21.
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403PubMedCrossRef
22.
Patel SS, Arrington AK, McKenzie S, Mailey B, Ding M, Lee W et al (2012) Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol 2012:253517PubMedPubMedCentralCrossRef
23.
Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA et al (2001) Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 7(7):631–636PubMedCrossRef
24.
DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS et al (2011) Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 253(1):166–172PubMedCrossRef
25.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10(1):35–43PubMedCrossRef
26.
Grat M, Wronka KM, Stypulkowski J, Bik E, Krasnodebski M, Masior L et al (2017) The Warsaw proposal for the use of extended selection criteria in liver transplantation for hepatocellular cancer. Ann Surg Oncol 24(2):526–534PubMedCrossRef
27.
Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J et al (2008) Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 14(8):1107–1115PubMedCrossRef
28.
Freeman RB, Edwards EB, Harper AM (2006) Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 6(6):1416–1421PubMedCrossRef
29.
Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR et al (2007) An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol 14(9):2608–2614PubMedCrossRef
30.
Baccarani U, Isola M, Adani GL, Benzoni E, Avellini C, Lorenzin D et al (2008) Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transpl Int 21(3):247–254PubMedCrossRef
31.
Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY (2013) Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 19(12):1343–1353PubMedCrossRef
32.
Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM (2008) Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 8(4 Pt 2):958–976PubMedCrossRef
33.
Xing M, Kim HS (2017) Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation. Cancer Med 6(1):26–35PubMedCrossRef
34.
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver IntLiver Int 35(9):2155–2166CrossRef
35.
Oligane HC, Close ON, Xing M, Kim HS (2017) Bridging locoregional therapy: longitudinal trends and outcomes in patients with hepatocellular carcinoma. Transplant Rev (Orlando)
36.
Magnetta MJ, Xing M, Zhang D, Kim HS (2016) The effect of bridging locoregional therapy and Sociodemographics on survival in hepatocellular carcinoma patients undergoing orthotopic liver transplantation: a united network for organ sharing population study. J Vasc Interv Radioll 27(12):1822–1828CrossRef
37.
Hoehn RS, Hanseman DJ, Wima K, Ertel AE, Paquette IM, Abbott DE et al (2015) Does race affect management and survival in hepatocellular carcinoma in the United States? Surgery 158(5):1244–1251PubMedCrossRef
38.
Harlan LC, Parsons HM, Wiggins CL, Stevens JL, Patt YZ (2015) Treatment of hepatocellular carcinoma in the community: disparities in standard therapy. Liver Cancer 4(1):70–83PubMedPubMedCentralCrossRef
39.
Yu JC, Neugut AI, Wang S, Jacobson JS, Ferrante L, Khungar V et al (2010) Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer 116(7):1801–1809PubMedPubMedCentralCrossRef
40.
Zak Y, Rhoads KF, Visser BC (2011) Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg 146(7):778–784PubMedCrossRef
41.
Fujiki M, Aucejo F, Choi M, Kim R (2014) Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol 20(18):5308–5319PubMedPubMedCentralCrossRef
42.
Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442PubMedCrossRef
43.
Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA (2006) Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6(11):2644–2650PubMedCrossRef
44.
Li H, Li B, Wei Y, Yan L, Wen T, Wang W et al (2015) Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: a single center 12-year experience. Clin Res Hepatol Gastroenterol 39(4):451–457PubMedCrossRef
45.
Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF et al (2006) Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 12(4):665–673PubMedCrossRef
46.
Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J et al (2017) Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a ten year intention-to-treat analysis. Hepatology
47.
Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R et al (2017) Stereotactic body radiotherapy versus TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol
48.
Sandroussi C, Dawson LA, Lee M, Guindi M, Fischer S, Ghanekar A et al (2010) Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 23(3):299–306PubMedCrossRef
49.
Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R et al (2007) Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 13(2):272–279PubMedCrossRef
50.
Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C et al (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41(5):1130–1137PubMedCrossRef
51.
Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M et al (2004) Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 4(5):782–787PubMedCrossRef
52.
Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK et al (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10(3):449–455PubMedCrossRef
53.
Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transp 9(6):557–563CrossRef
54.
Kim JM, Kwon CH, Joh JW, Choi MS, Lee JH, Koh KC et al (2012) Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria. Transplant Proc 44(2):403–408PubMedCrossRef
55.
Manini MA, Sangiovanni A, Martinetti L, Vigano D, La Mura V, Aghemo A et al (2015) Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl 21(10):1259–1269PubMedCrossRef
56.
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52PubMedCrossRef
57.
Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D et al (2013) Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 58(1):73–80PubMedCrossRef
58.
Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D et al (2014) Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 60(1):192–201PubMedCrossRef
59.
Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A et al (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(6):1155–1163 e2 PubMedCrossRef
60.
Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47(1):82–89PubMedCrossRef
61.
Facciorusso A, Serviddio G, Muscatiello N (2016) Local ablative treatments for hepatocellular carcinoma: an updated review. World J Gastrointest Pharmacol Ther 7(4):477–489PubMedPubMedCentralCrossRef
62.
Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P et al (2014) The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol 21(3):e480–e492PubMedPubMedCentralCrossRef
63.
Koffron AJ, Auffenberg G, Kung R, Abecassis M (2007) Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 246(3):385–392 discussion 92-4 PubMedPubMedCentralCrossRef
64.
Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104(2):514–524PubMedCrossRef
65.
Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R et al (2003) Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 14(10):1267–1274PubMedCrossRef
66.
Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R et al (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240(5):900–909PubMedPubMedCentralCrossRef
67.
Agopian VG, Morshedi MM, McWilliams J, Harlander-Locke MP, Markovic D, Zarrinpar A et al (2015) Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg 262(3):536–545 discussion 43-5 PubMedCrossRef
68.
Vasnani R, Ginsburg M, Ahmed O, Doshi T, Hart J, Te H et al (2016) Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation. Hepatobiliary Surg Nutr 5(3):225–233PubMedPubMedCentralCrossRef
69.
Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S et al (2005) Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 11(9):1117–1126PubMedCrossRef
70.
Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J et al (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81(4):e447–e453PubMedCrossRef
71.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34PubMedCrossRef
72.
Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P et al (2010) Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 51(1):165–173PubMedCrossRef
73.
Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I et al (2008) Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 8:349PubMedPubMedCentralCrossRef
74.
Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O et al (2015) Impact of neo-adjuvant sorafenib treatment on liver transplantation in HCC patients—a prospective, randomized, double-blind, phase III trial. BMC Cancer 15:392PubMedPubMedCentralCrossRef
75.
Cescon M, Cucchetti A, Ravaioli M, Pinna AD (2013) Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 58(3):609–618PubMedCrossRef
76.
Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K et al (2012) Loco-regional therapy in patients with Milan criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. HPB (Oxford) 14(5):325–332CrossRef
77.
Crocetti L, de Baere T, Lencioni R (2010) Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 33(1):11–17PubMedCrossRef
78.
Lencioni R, Petruzzi P, Crocetti L (2013) Chemoembolization of hepatocellular carcinoma. Semin Interv Radiol 30(1):3–11CrossRef
79.
Mosconi C, Cappelli A, Pettinato C, Golfieri R (2015) Radioembolization with yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J Hepatol 7(5):738–752PubMedPubMedCentralCrossRef
80.
Rim CH, Seong J (2016) Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J 34(3):160–167PubMedPubMedCentralCrossRef
81.
Sanuki N, Takeda A, Kunieda E (2014) Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 20(12):3100–3111PubMedPubMedCentralCrossRef
Metadata
Title
Bridging to liver transplantation in HCC patients
Authors
Dagmar Kollmann
Nazia Selzner
Markus Selzner
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 6/2017
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1609-2

Other articles of this Issue 6/2017

Langenbeck's Archives of Surgery 6/2017 Go to the issue

ORIGINAL ARTICLE

Chronic pain and quality of life after inguinal hernia repair using the COMI-hernia score

ORIGINAL ARTICLE

Risk factors for morbidity after appendectomy

ORIGINAL ARTICLE

Prognostic value of intraoperative neural monitoring of the recurrent laryngeal nerve in thyroid surgery

ORIGINAL ARTICLE

Gastric bypass simultaneously improves adipose tissue function and insulin-dependent type 2 diabetes mellitus

ORIGINAL ARTICLE

Contribution of intraoperative neural monitoring to preservation of the external branch of the superior laryngeal nerve: a randomized prospective clinical trial

How-I-Do-It Article

Laparoscopic proximal gastrectomy with oblique jejunogastrostomy